U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H31NO.C4H4O4
Molecular Weight 417.5384
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of DERAMCICLANE FUMARATE

SMILES

OC(=O)\C=C\C(O)=O.CN(C)CCO[C@@]1(C[C@H]2CC[C@]1(C)C2(C)C)C3=CC=CC=C3

InChI

InChIKey=RFQWRWCCNQNACG-HJYQBBATSA-N
InChI=1S/C20H31NO.C4H4O4/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16;5-3(6)1-2-4(7)8/h6-10,17H,11-15H2,1-5H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t17-,19-,20+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C20H31NO
Molecular Weight 301.4662
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Deramciclane is camphor derivative. It is an anxiolytic agent that binds with high affinity to 5-HT2A/2C receptor. Deramciclane showed significant evidence of efficacy for the treatment of generalized anxiety disorder in adult patients. A single dose of deramciclane was rapidly absorbed with peak plasma concentrations being reached after about 3 h. Deramciclane has a half-life of around 27 h. The most commonly reported adverse event was headache. In the in vitro studies deramciclane concentration-dependently inhibited NMDA evoked spreading depression.

Approval Year

PubMed

PubMed

TitleDatePubMed
Selective binding interactions of deramciclane to the genetic variants of human alpha(1)-acid glycoprotein.
2010-03
Deramciclane improves object recognition in rats: potential role of NMDA receptors.
2010-02
Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.
2008-01
Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
2005-12
Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human.
2005-11
Role of CYP2E1 in deramciclane metabolism.
2005-11
Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers.
2004-11
Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers.
2004-08
Comparison of deramciclane to benzodiazepine agonists in behavioural activity of mice and in alcohol drinking of alcohol-preferring rats.
2004-04
Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
2004-02
Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone.
2003-12
The effect of oil as a dietary component on in vitro dissolution of an acid-labile drug.
2003-07
Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration.
2003
Studies of the side chain cleavage of deramciclane in rats with radiolabelled compounds.
2002-03
In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers.
2002-03
Deramciclane (Egis).
2002-02
8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze.
2001-01
Patents

Patents

Sample Use Guides

60 mg/day
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:57:21 GMT 2025
Edited
by admin
on Mon Mar 31 17:57:21 GMT 2025
Record UNII
W1183TY0EE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EGIS-3886
Preferred Name English
DERAMCICLANE FUMARATE
MI  
Common Name English
DERAMCICLANE FUMARATE [MI]
Common Name English
Code System Code Type Description
FDA UNII
W1183TY0EE
Created by admin on Mon Mar 31 17:57:21 GMT 2025 , Edited by admin on Mon Mar 31 17:57:21 GMT 2025
PRIMARY
PUBCHEM
6438165
Created by admin on Mon Mar 31 17:57:21 GMT 2025 , Edited by admin on Mon Mar 31 17:57:21 GMT 2025
PRIMARY
CAS
120444-72-6
Created by admin on Mon Mar 31 17:57:21 GMT 2025 , Edited by admin on Mon Mar 31 17:57:21 GMT 2025
PRIMARY
SMS_ID
300000056991
Created by admin on Mon Mar 31 17:57:21 GMT 2025 , Edited by admin on Mon Mar 31 17:57:21 GMT 2025
PRIMARY
MERCK INDEX
m4186
Created by admin on Mon Mar 31 17:57:21 GMT 2025 , Edited by admin on Mon Mar 31 17:57:21 GMT 2025
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY